Prognosis
Pfizer-BioNTech Covid Vaccine Blocks Most Spread in Israel Study
A nurse administers the Pfizer-BioNTech Covid-19 vaccine in Holon, Israel.
Photographer: Kobi Wolf/BloombergThis article is for subscribers only.
Pfizer Inc. and BioNTech SE’s coronavirus vaccine blocked 94% of asymptomatic infections in an Israeli study that further builds the case for the shot’s overwhelming effectiveness against the virus a year after the pandemic began.
The vaccine stopped 97% of symptomatic cases, hospitalizations and deaths, the companies and the Israeli Ministry of Health said on Thursday. Crucially, the results were measured two weeks after the second dose, suggesting that high efficacy seen after the first dose of the shot may be even better once vaccination is complete.